1) Sachdev, P.S., Lipnicki, D.M., Crawford, J., Reppermund, S., Kochan, N.A., Trollor, J.N., Wen, W., Draper, B., Slavin, M.J., Kang, K. and Lux, O., 2013. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One, 8(3), p.e59649.
2) Thomas, K.R., Eppig, J.S., Edmonds, E.C., Jak, A.J., Delano-Wood, L., Salmon, D.P., Edland, S.D. and Bondi, M.W., 2017. ARTIFICIALLY HIGH MCI DIAGNOSTIC STABILITY AND LOW REVERSION RATES IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 13(7), pp.P817-P818.
3) Park, M.H. and Han, C., 2015. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer’s disease biomarkers profiles. International Psychogeriatrics, 27(3), pp.429-437.
4) Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012;33:1203–1214
5) Kumar R, Jorm AF, Parslow RA, Sachdev PS (2006) Depression in mild cognitive impairment in a community sample of individuals 60–64 years old. Int Psychogeriatr 18: 471–480.
6) Olazaran J, Torrero P, Cruz I, Aparicio E, Sanz A, et al. (2011) Mild cognitive impairment and dementia in primary care: the value of medical history. Fam Pract 28: 385–392.
7) Wisotsky M, Friedman JH (1965) Problems of Psychologic Testing with Aged Patients in a Geriatric Mental Hygiene Clinic. J Am Geriatr Soc 13: 243–247.
8) Petersen RC (2011) Clinical practice. Mild cognitive impairment. N Engl J Med 364: 2227–2234.
9) Ganguli M, Snitz BE, Saxton JA, Chang C-CH, Lee C-W, et al. (2011) Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 68: 761–767.
10) Dolcos S, MacDonald SW, Braslavsky A, Camicioli R, Dixon RA (2012) Mild cognitive impairment is associated with selected functional markers: integrating concurrent, longitudinal, and stability effects. Neuropsychology 26: 209–223.
11) Koepsell TD, Monsell SE (2012) Reversion from mild cognitive impairment to normal or near-normal cognition: Risk factors and prognosis. Neurology 79: 1591–1598.
12) Diniz BS, Nunes PV, Yassuda MS, Forlenza OV (2009) Diagnosis of mild cognitive impairment revisited after one year. Preliminary results of a prospective study. Dement Geriatr Cogn 27: 224–231.
13) Loewenstein DA, Acevedo A, Small BJ, Agron J, Crocco E, et al. (2009) Stability of different subtypes of mild cognitive impairment among the elderly over a 2- to 3-year follow-up period. Dement Geriatr Cogn Disord 27: 418–423.
14) Manly JJ, Tang MX, Schupf N, Stern Y, Vonsattel JP, et al. (2008) Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 63: 494–506.
15) Tokuchi R, Hishikawa N, Kurata T, et al. Clinical and demographic predictors of mild cognitive impairment for converting to Alzheimer’s disease and reverting to normal cognition. J Neurol Sci 2014.
16) Moradi, E., Hallikainen, I., Hänninen, T., Tohka, J., and Alzheimer’s Disease Neuroimaging Initiative (2016). Rey’s auditory verbal learning test scores can be predicted from whole brain MRI in Alzheimer’s disease. Neuroimage Clin. 13, 415–427.
17) O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Archives of neurology. 2008 Aug 11;65(8):1091-5.
18) Horowitz F. Developmental theory, prediction, and the developmental equation in follow-up research. In: Friedman S, Haywood HC, editors. Developmental Follow-up: Concepts, Domains, and Methods. Academic Press; San Diego. CA: 1994. pp. 27–44.
19) Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: Mini-Mental State Examination and Clinical Dementia Rating. Am J Geriar Psychiatry. 2006;14(2):139–144.
20) Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1154–1166.
21) Leber P. Guidelines for the Clinical Evaluahon of Antidementia Drugs. US Food and Drug Administration; Rockville. MD: 1990.
22) Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572. 
23) Berg L, Miller JP, Storandt M, et al. Mild senile dementia of the Alzheimer type, 2: longitudinal assessment. Ann Neurol. 1988;23(5):477–484.
24) Lynch CA, Walsh C, Blanco A, et al. The clinical dementia rating sum of box score in mild dementia. Dement Geriatr Cogn Disord. 2006;21(1):40–43.
25) McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944.
26) Petersen RC, editor. Mild Cognitive Impairment: Aging to Alzheimer's Disease. Oxford University Press; New York, NY: 2003.
27) Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414. 
28) Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 1997;48(6):1508–1510.
29) Burke WJ, Miller JP, Rubin EH, et al. Reliability of the Washington University Clinical Dementia Rating. Arch Neurol. 1988;45(1):31–32. 
30) Berg L, McKeel DW, Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50(4):349–358. 
31) Morris JC, McKeel DW, Jr, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991;41(4):469–478. 
32) Morris JC, Storandt M, McKeel DW, Jr, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46(3):707–719. 
33) Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59–66. 
34) Andersen K, Lolk A, Kragh-Sorensen P, Petersen NE, Green A. Depression and the risk of Alzheimer disease. Epidemiology. 2005;16(2):233–238. 
35) Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B, Alzheimer's Disease Neuroimaging Initiative. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials. Alzheimer's & Dementia. 2013 Feb 1;9(1):S45-55.
36) Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. Journal of Alzheimer's Disease. 2018 Jan 1(Preprint):1-22.
37) MMSE: https://www.mountsinai.on.ca/care/psych/on-call-resources/on-call-resources/mmse.pdf
